ATS 2023 Respiratory Innovation Summit
During the ATS 2023 Respiratory Innovation Summit, APIE Therapeutics presented a poster demonstrating preclinical efficacy of APT101 in a lung fibrosis model
IPF Summit 2022
During the IPF Summit, APIE Therapeutics presented a poster describing the novel apelin receptor agonist (APT101) and its effects in models of acute and chronic lung injury
International Workshop of Scleroderma Research
Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases associated with SSc-ILD
